30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)
- Poster presentation
- Open Access
- Published:
Comparative study of sequential intravesical chemotherapy using gemcitabine and mitomycin C with mitomycin C alone for non-muscle invasive bladder carcinoma- a randomized trial
Journal for ImmunoTherapy of Cancer volume 3, Article number: P136 (2015)
Introduction
This study was conducted to investigate the ablative efficacy and safety of sequential intravesical gemcitabine and mitomycin C with mitomycin C alone in refractory non-muscle invasive bladder cancer (NMIBC).
Methods
A total of 219 patients with refractory NMIBC were prospectively enrolled at tertiary academic center over period of Feb 2009-Jan 2012 & followed for next 3 yrs. They were randomly assigned to either of treatment arms: Gentamycin & mitomycin C (group A) or mitomycin C (group B). All patients underwent a 6-week induction regimen followed by a monthly maintenance regimen for one year if they responded to the induction course.
Results
In Group A 98 of 102 & in group B 94 of 96 patients completed the therapy and were evaluated for response while 6 patient left the therapy in between. The therapy was well tolerated in the rest of patients. In group‘A’ i.e Gentamycin & mitomycin C a total, 82 patients (83.67%) exhibited a complete response to intravesical therapy. In 12.2% (12) patients had biopsy proven recurrence (22±6.16 months). In group ‘B’ (mitomycin C), 63 (65.60%) patients exhibited a complete response to intravesical therapy, 22 patients (22.9%) showed a partial response. During follow-up, 16 patients (25.3%) developed recurrence within this period. (14.5 +/- 8.26 months).
Conclusions
Chemoresection with sequential intravesical gemcitabine and mitomycin C administration may be a viable option for BCG refractory non-muscle invasive bladder cancer (NMIBC).

Figure 2
Author information
Authors and Affiliations
Rights and permissions
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
Jayant, K., Kumar, S., Singh, S.k. et al. Comparative study of sequential intravesical chemotherapy using gemcitabine and mitomycin C with mitomycin C alone for non-muscle invasive bladder carcinoma- a randomized trial. j. immunotherapy cancer 3 (Suppl 2), P136 (2015). https://doi.org/10.1186/2051-1426-3-S2-P136
Published:
DOI: https://doi.org/10.1186/2051-1426-3-S2-P136
Keywords
- Gemcitabine
- Partial Response
- Mitomycin
- Viable Option
- Gentamycin